» Articles » PMID: 6994791

The Effect of Metoclopramide and Atropine on the Absorption of Orally Administered Mexiletine

Overview
Specialty Pharmacology
Date 1980 May 1
PMID 6994791
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

The effect of pretreatment with intravenous metoclopramide (10 mg) and atropine (0.6 mg), both separately and combined, on the absorption rate and relative oral bioavailability of the antiarrhythmic drug, mexiletinee (400 mg) was studied in eight fasting healthy males using a Latin Square design for order of pretreatment administration. The time (Tmax) of the maximum mexiletin plasma concentration (Cpmax) was reduced by metoclopramide (P < 0.001) and was increased by atropine (P < 0.01) compared with saline control. Tmax was not significantly altered by combined metoclopramide and atropine pretreatment. Atropine pretreatment was associated with a significant reduction of Cpmax (P < 0.05) and of elimination half-life (P < 0.05). The area under the mexiletine plasma concentration-time curve was not affected by any of the pretreatments. The results suggested that metoclopramide enhanced and atropine decreased the rate of mexiletine absorption without altering the relative oral bioavailability. When the pretreatments were administered in combination, metoclopramide reversed the delay in mexiletine absorption produced by atropine.

Citing Articles

Pharmacokinetic and pharmacodynamic studies of drug interaction following oral administration of imipramine and sodium alginate in rats.

Watanabe S, Suemaru K, Inoue N, Imai K, Aimoto T, Araki H Naunyn Schmiedebergs Arch Pharmacol. 2008; 378(1):85-91.

PMID: 18449531 DOI: 10.1007/s00210-008-0297-4.


Clinical pharmacokinetics of mexiletine.

Labbe L, Turgeon J Clin Pharmacokinet. 1999; 37(5):361-84.

PMID: 10589372 DOI: 10.2165/00003088-199937050-00002.


Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.

Greiff J, Rowbotham D Clin Pharmacokinet. 1994; 27(6):447-61.

PMID: 7882635 DOI: 10.2165/00003088-199427060-00004.


Plasma mexiletine concentrations following combined oral and intramuscular administration.

Bradbrook I, Feldschreiber P, Morrison P, Rogers H, Spector R Eur J Clin Pharmacol. 1981; 19(4):301-4.

PMID: 7286033 DOI: 10.1007/BF00562808.


Population pharmacokinetic parameters in patients treated with oral mexiletine.

Vozeh S, Katz G, Steiner V, Follath F Eur J Clin Pharmacol. 1982; 23(5):445-51.

PMID: 7151850 DOI: 10.1007/BF00605996.


References
1.
Koch-Weser J, KLEIN S . Procainamide dosage schedules, plasma concentrations, and clinical effects. JAMA. 1971; 215(9):1454-60. View

2.
Levy G, Gibaldi M, PROCKNAL J . Effect of an anticholinergic agent on riboflavin absorption in man. J Pharm Sci. 1972; 61(5):798-9. DOI: 10.1002/jps.2600610529. View

3.
Nimmo J, Heading R, Tothill P, Prescott L . Pharmacological modification of gastric emptying: effects of propantheline and metoclopromide on paracetamol absorption. Br Med J. 1973; 1(5853):587-9. PMC: 1589913. DOI: 10.1136/bmj.1.5853.587. View

4.
Adjepon-Yamoah K, Scott D, Prescott L . Impaired absorption and metabolism of oral lignocaine in patients undergoing laparoscopy. Br J Anaesth. 1973; 45(2):143-7. DOI: 10.1093/bja/45.2.143. View

5.
Mearrick P, Wade D, Birkett D, Morris J . Metoclopramide, gastric emptying and L-dopa absorption. Aust N Z J Med. 1974; 4(2):144-8. DOI: 10.1111/j.1445-5994.1974.tb03163.x. View